Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 129.73B P/E 18.00 EPS this Y -89.20% Ern Qtrly Grth -19.00%
Income -6.54B Forward P/E 8.64 EPS next Y 819.70% 50D Avg Chg -4.00%
Sales 46.51B PEG -14.47 EPS past 5Y 10.73% 200D Avg Chg -12.00%
Dividend 4.00% Price/Book 4.03 EPS next 5Y -4.81% 52W High Chg -24.00%
Recommedations 2.80 Quick Ratio 0.94 Shares Outstanding 2.03B 52W Low Chg 3.00%
Insider Own 0.11% ROA 6.00% Shares Float 2.02B Beta 0.46
Inst Own 77.93% ROE -26.59% Shares Shorted/Prior 21.79M/28.01M Price 61.75
Gross Margin 76.18% Profit Margin -14.06% Avg. Volume 8,754,443 Target Price 52.25
Oper. Margin 21.29% Earnings Date Oct 31 Volume 9,548,659 Change 0.36%
About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company News
12/21/24 Want Decades of Passive Income? 3 Stocks to Buy Right Now
12/19/24 Jim Cramer on Bristol-Myers Squibb Company (BMY): ‘This Stock Has Been Hot Since The Summer’
12/19/24 Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
12/19/24 Bristol Myers Squibb Stock Earns 83 RS Rating
12/19/24 Jim Cramer on Bristol-Myers Squibb (BMY): Why Schizophrenia Drug Cobenfy Could Change the Game
12/19/24 3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income
12/19/24 Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
12/19/24 Got $250? 2 Healthcare Stocks to Buy and Hold Forever
12/19/24 These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?
12/18/24 Is Bristol-Myers Squibb Company (BMY) the Best Cash-Rich Dividend Stock to Invest In Now?
12/18/24 Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
12/17/24 Is Bristol-Myers Squibb Company (BMY) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
12/17/24 Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline
12/16/24 Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
12/16/24 Jefferies Upgrades Bristol Myers Squibb to ‘buy’ on drug Cobenfy
12/16/24 BMY vs. VRTX: Which Stock Is the Better Value Option?
12/15/24 Bristol-Myers Squibb (NYSE:BMY) Will Pay A Larger Dividend Than Last Year At $0.62
12/13/24 Bristol Myers Squibb (BMY) Stock Moves -0.89%: What You Should Know
12/13/24 Top Analyst Reports for Visa, Linde & Thermo Fisher Scientific
12/12/24 Why Bristol-Myers Squibb (BMY) Is Among the Best Long-Term Dividend Stocks to Invest in Right Now
BMY Chatroom

User Image TalkMarkets Posted - 11 hours ago

Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 21 $BMY $M $SYF $SEDG $F https://talkmarkets.com/content/stocks--equities/wall-streets-top-10-stock-calls-this-week-saturday-dec-21?post=474977

User Image Stocksrunner Posted - 11 hours ago

$BMY Bristol-Myers Squibb is moving past a key level of resistance at $54.36. The RSI shows it's gaining strength, and with 45M+ volume, more buyers are getting in. This could mean more gains ahead! https://stocksrunner.com/symbol/BMY

User Image Yloo Posted - 1 day ago

$NMRA 0.85m shares dumped at the close. Leaking? Not necessarily. This dumping didn't cause a price collapse. So it's likely rebalancing the position on the quadruple option expiration day. This can also be observed in all major stocks NVDA SMCI $TSLA $LLY, $BMY But it doesn't mean Monday won't be a PR day for ph3 readout. WO. My thesis: high success rate in PH3, much higher than prostate cancer vaccine $CADL, but CADL succeeded in its ph3 readout. And NMRA is so out of the mainstream that it may surprise the street on the positive side but with subdued negative impact. No one is buying and holding it, so not many people could dump it. we should see. @Doozio Take a look at this

User Image DividendPower Posted - 1 day ago

Recent Dividend Increases - Updated 12/20/24 https://www.dividendpower.org/dividend-increases/ $ANDE $ERIE $THFF $MA $BMY

User Image Deenjdeenj Posted - 1 day ago

$BMY Yessirrr!! 🚀🚀

User Image Paco_the_Dirty_Gringo Posted - 1 day ago

$PTIX’s work in CNS treatments is rapidly progressing. If you’ve seen $BMY’s success in oncology, $PTIX could be your next biotech opportunity with huge growth potential in mental health.

User Image ThisIsBiotech Posted - 1 day ago

$BMY Is Cereno Scientific the Next Big Deal? CS1 vs. Sotatercept Sotatercept (now Winrevair), Acceleron’s PAH candidate, drove Merck’s $11.5 billion acquisition, with analysts estimating it accounted for 70–80% of the deal value. BMS, a major shareholder in Acceleron, reportedly considered raising its bid but ultimately lost to Merck. Now, Cereno's CS1 is emerging as a best-in-class, disease-modifying treatment with the potential to surpass Sotatercept. Early data highlights CS1’s novel mechanism, strong efficacy, and favorable safety profile. Compassionate use approvals and topline results further validate its promise. World-renowned Dr.Deepak Bhatt, who serves on BMS’s board, is also a member of Cereno's Scientific Advisory Board, providing a unique connection between the two companies. With the PAH market valued at over $7B and a CAGR exceeding 5%, the opportunity is massive. Having missed Winrevair, BMS could now see CS1 as its next blockbuster target in PAH treatment.

User Image JuggernautRaider Posted - 2 days ago

$PPBT agreed @Smittysixty - PPBT is insanely undervalued like $JFBR and $TNXP . I want to read up more on their agreement with $BMY on CM24 given it is administered with Opdivo & Standard/of-care chem in 2L+ pancreatic cancer. I wonder if $BMY has a poison pill to acquire them or partner. If so, it would explain why they have not started hiring American employees to commercialize here as BMS may just buy them out (CM24 is a divested BMS asset If I recall correctly). @PurpleBiotech & @purplebison : check out this @Beautiful @biotech @Pipelines4Life :

User Image Deenjdeenj Posted - 2 days ago

$BMY Flying Friday tomorrow 💸💸

User Image lcc007 Posted - 2 days ago

$BMY Latest SMA AI Forecast

User Image lcc007 Posted - 2 days ago

@Wigglyick $BMY here ya go!

User Image SniperPro Posted - 2 days ago

$LXRX THE MAN behind SOTA research... check this out: Dr Deepak L. Bhatt Underscores Sotagliflozin Benefits Seen in SOLOIST, SCORED https://www.ajmc.com/view/dr-deepak-l-bhatt-underscores-sotagliflozin-benefits-seen-in-soloist-scored He's currently a board director at $BMY https://www.bms.com/about-us/leadership/board-of-directors/deepak-l-bhatt.html Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2030183 Authors: Deepak L. Bhatt, M.D., M.P.H. , Michael Szarek, Ph.D., P. Gabriel Steg, M.D., Christopher P. Cannon, M.D. , Lawrence A. Leiter, M.D., Darren K. McGuire, M.D., M.H.Sc., Julia B. Lewis, M.D., +12 , for the SOLOIST-WHF Trial Investigators FDA DO THE RIGHT THING... DIABETES COMMUNITY WORLDWIDE IS EXPECTING YOUR BEST!!!

User Image Kaykay610 Posted - 2 days ago

$BMY https://youtu.be/AVLvWEFcgNI?si=k7i2vWsvPeBP4tAc

User Image Walter100 Posted - 2 days ago

$BMY : Has a strong oncology portfolio with drugs like Opdivo (nivolumab), but their effectiveness in gastric cancer is modulated by PD-L1 expression levels (CPS). DKN-01's effectiveness regardless of PD-1/PD-L1 expression could expand their treatment options, potentially reaching a broader patient population.

User Image GPS_OS_21_vs_SOC_5 Posted - 2 days ago

$SLS @Jackedmoney Yes - I do, and I might be Happier. The Math Stacks Up for Just Gps Being Worth $24B to Big Pharmaceutical Just for AML... That's a $6B TAM at a 4x price to Sales Ratio - smaller Pharma's have 10x Price to sales market caps. . . $10B is a 40% dNPV for just Gps w in AML. Its Use in Gps Opdivo $BMY combo in Mesothelioma 28 months of OS for Responders vs 28 weeks wSOC - Gps Keytruda $MRK 18.4 months of Os in PROC vs 16.46 for Elahere that GOT BOUGHT for 10.1B... so yes then Add 009 Value - BP knows right now based not the Safety Profile its getting fda approval, 100% CR rates for end stage, post ven relapsed R/R AML patients, a Not Yet Met OS, Already 3X + longer than historical norms. - $ABBV $RHHBY $BMY - Ven and Aza owners all could easily rationalize a multibillion dollar 009 buy, just for the 30,000 ASXL1+ AML/MDS patients dxd each year.

User Image PFElinepfrenzy1990 Posted - 2 days ago

$PFE $BMY $AZN $LLY - Well, I suppose healthcare bad AI good 🙄 who needs healthcare when we have Blackwell chips and self-driving cars and quantum computing?

User Image SPG565 Posted - 2 days ago

$BMY Priced for total earnings of $3.50 in 2025. What happens when they make possibly $7? 🤔

User Image OptionSamurai Posted - 2 days ago

$BMY appears in our Dividend Capture scan. The idea is to buy shares + sell call to enjoy premium and the dividend. ☑ The Fundamental score is 9 ☑ Growth score is 9 ☑ Dividend date 03-Jan-25 ☑ IV Percentile is 58.7% Covered Call 57.0, 03-Jan-25: 📈 An annualized return of 36.7% 📉 The breakeven point is 1.5% 👉 See more results & customize here: https://bit.ly/3lR1xIP

User Image Apr4609 Posted - 2 days ago

@Walter100 Furthermore, I doubt retailers at $BMY, $MRK, $BGNE care about gastric cancer (maybe beigene) but leap is about to show that adding dkn-01 to one of their pd-1 will make the other companies obsolete unless they add other products to their pd-1 Global reach and other collaborations with $gild and $roche are also in the background

User Image Article_AI Posted - 2 days ago

$BMY 3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money. While the average stock on the S&P 500 might pay just an average of 1.2%, there are many other stocks out there that pay much higher than that -- and they aren't risky investments to hold in your portfolio. https://www.stck.pro/news/BMY/96530880/

User Image ThisIsBiotech Posted - 2 days ago

The deal grants $BMY global rights to BioArctic's preclinical antibody candidates, BAN1503 and BAN2803, aimed at treating Alzheimer's disease. The agreement includes an upfront payment of $100 million, with potential milestone payments bringing up to $1.3 billion In light of BMS's recent collaborations, attention is turning at innovative SWE Biotech. Cereno Scientific, has developed CS1, a novel treatment for PAH. PAH with a market of $ 7B anually and a CAGR of 5%. CS1 is an HDAC inhibitor that works through epigenetic modulation, aiming to reverse the pathological vascular remodeling of the small lung arteries associated with PAH. The recent positive Phase IIa trial results for CS1 demonstrated a favorable safety profile and compelling signs of clinical efficacy. CU from FDA accepted and pivotal trail is the next step. Given BMS's history of strategic acquisitions and partnerships, CS1 presents a compelling opportunity. That would give BMS with a novel therapeutic avenue in PAH.

User Image Article_AI Posted - 2 days ago

$BMY Got $250? 2 Healthcare Stocks to Buy and Hold Forever One of the great things about the stock market is that one doesn't have to be a genius or a multimillionaire to take advantage of its wealth-building power. A person who starts out even with a relatively modest sum, like $250, then progressively (and consistently) invests more over time, and stays invested for the long term, will typically see their efforts yield significant returns -- provided they choose the right companies to buy. https://www.stck.pro/news/BMY/96519121/

User Image Article_AI Posted - 2 days ago

$BMY These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy? It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry. The key reason is simple: Drug development is a frequently laborious and expensive process that can swallow vast amounts of capital. https://www.stck.pro/news/BMY/96516801/

User Image DMcL Posted - 2 days ago

$RVPH Comparison of the rollover patients efficacy from Reviva and $BMY drugs. TLDR. Reviva has better efficacy on a small subset of Rollover patients, full OLE data required for more accurate comparison. Key takeaway: Brilaroxazine's efficacy is comparable to Cobenfy from early data.

User Image Capitulation_0 Posted - 3 days ago

$CYTK May be better asa standalone company: RBC Capital⬆️the PT on $CYTK to $82 was $80/Outperform, says "With the potential aficamten launch trajectory top of mind for many investors, we took the time to review the launch of the closest comparable drug - BMY's Camzyos:" $BMY $BAYRY $EWTX "Our analysis suggests that the Camzyos launch was better than investor sentiment around it seems to imply, and that if aficamten meets or exceeds the Camzyos trajectory, it could be among the more successful launches among near-term approvals. Given the potential advantages aficamten may have on efficacy, as well as the convenience of the drug, we believe aficamten is likely to do better than Camzyos, and we expect a strong launch that can provide line of sight to a >$3.6B opportunity. With shares not fully appreciating the opportunity, we would be buyers. Tgt to $82 on model updates based on the recent Bayer partnership." https://x.com/Quantumup1/sta/Quantumup1/status/1846984773698281983

User Image SPG565 Posted - 3 days ago

$PFE $BMY $C Absolutely ridiculous selling. I'd add if you have cash or sell Puts

User Image MF__DOOM Posted - 3 days ago

$BMY $56 potentially breaking down $SPY $QQQ

User Image MF__DOOM Posted - 3 days ago

$BMY hold $56 for today

User Image JuggernautRaider Posted - 3 days ago

$PPBT your PPS expectations are reasonable @iambaron . @PPBT4LYFE knows: @PurpleBiotech is a WINNER! They need to start hiring North American employees with pancreatic cancer experience from $BMY or $RVMD or even $NVCR to show they are preparing for launch. They may need a phase 3 but a 2 month OS in 2L pancreatic cancer is significant.

User Image achr_trader Posted - 3 days ago

$BMY

Analyst Ratings
BMO Capital Market Perform Sep 27, 24
BMO Capital Market Perform Sep 23, 24
Cantor Fitzgerald Neutral Sep 16, 24
Jefferies Hold Aug 28, 24
Barclays Underweight Aug 22, 24
TD Cowen Hold Aug 12, 24
Barclays Underweight Jul 29, 24
Deutsche Bank Hold Jul 23, 24
Cantor Fitzgerald Neutral Jul 22, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BOERNER CHRISTOPHER S. Chief Executive Offi.. Chief Executive Officer Dec 05 Buy 49.78 2,000 99,560 82,672 12/07/23
BOERNER CHRISTOPHER S. Chief Executive Offi.. Chief Executive Officer Nov 28 Buy 48.86 3,071 150,049 79,384 11/30/23
Samuels Theodore R. II Director Director Nov 20 Buy 49.81 8,500 423,385 35,500 11/21/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Aug 24 Sell 61.25 17,986 1,101,642 27,868 08/28/23
Plenge Robert M EVP, Chief Research.. EVP, Chief Research Officer Aug 03 Sell 61.14 732 44,754 6,584 08/07/23
VESSEY RUPERT EVP & President, Res.. EVP & President, Research May 03 Sell 67.06 50,385 3,378,818 47,751 05/04/23
Caforio Giovanni Board Chair and CEO Board Chair and CEO Feb 06 Sell 74.65 240,000 17,916,000 236,104 02/08/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Feb 06 Sell 74.69 11,183 835,258 23,043 02/08/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Nov 09 Sell 80.45 16,250 1,307,312 34,226 11/14/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 07 Option 54.85 52,604 2,885,329 102,989 11/09/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 07 Sell 78.88 45,910 3,621,381 57,079 11/09/22
Elkins David V EVP, Chief Financial.. EVP, Chief Financial Officer Sep 13 Sell 71.32 133,951 9,553,385 119,786 09/15/22
Elkins David V EVP, Chief Financial.. EVP, Chief Financial Officer Sep 13 Option 48.49 123,277 5,977,702 223,737 09/15/22
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Sep 14 Sell 70.75 25,000 1,768,750 50,476 09/15/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Jun 13 Sell 74.04 30,000 2,221,200 551,104 06/14/22
LEUNG SANDRA EVP, General Counsel EVP, General Counsel Jun 06 Sell 74.89 65,000 4,867,850 308,627 06/07/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Mar 21 Sell 71.52 25,000 1,788,000 581,524 03/23/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Mar 16 Option 53.64 47,305 2,537,440 93,613 03/18/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Mar 16 Sell 69.25 74,559 5,163,211 50,385 03/18/22
Santiago Karen Murphy SVP & Controller SVP & Controller Mar 14 Sell 69.195 6,577 455,096 16,704 03/16/22
BOERNER CHRISTOPHER S. EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 14 Sell 69.197 29,532 2,043,526 41,966 03/16/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Feb 24 Sell 67 30,000 2,010,000 453,455 02/28/22
von Autenried Paul EVP, Chief Informati.. EVP, Chief Information Officer Nov 22 Sell 57.19 51,134 2,924,353 63,536 11/24/21
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Option 48.03 52,213 2,507,790 98,355 11/23/20
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Sell 61.28 57,591 3,529,176 51,343 11/23/20